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Background: Akt is a serine/threonine kinase that mediates signaling downstream of tyrosine kinase receptors like
the type I insulin-like growth factor receptor (IGF-IR). In fact, we have previously shown that mammary tumors
induced by elevated expression of the IGF-IR are associated with hyperactivation of Akt. However, there are three
mammalian isoforms of Akt (Akt1, Akt2 and Akt3) and these isoforms regulate distinct physiologic properties within
cells. In this manuscript, the impact of disrupting Akt1 or Akt2 in mammary tumors induced by IGF-IR
overexpression were examined to determine whether specific Akt isoforms regulate different aspects of mammary
tumorigenesis.
Methods: Akt1 and Akt2 levels were stably ablated in mammary tumors of MTB-IGFIR transgenic mice by crossing
MTB-IGFIR transgenic mice with either Akt1−/− or Akt2−/− mice. Tumor onset, growth rate, and metastasis were
determined.
Results: Ablation of Akt1 or Akt2 significantly delayed tumor onset and tumor growth rate but did not significantly
alter lung metastasis. Despite the absence of Akt1 or Akt2, mammary tumors that developed in the MTB-IGFIR mice
maintained detectable levels of phosphorylated Akt. Disruption of Akt1 or Akt2 did not affect cell morphology or
the expression of luminal or basal cytokeratins in mammary tumors.
Conclusions: Although loss of Akt1 or Akt2 significantly inhibited mammary tumor onset and growth rates the
effects were less dramatic than anticipated. Despite the complete loss of Akt1 or Akt2, the level of total
phosphorylated Akt remained largely unaffected in the mammary tumors suggesting that loss of one Akt isoform is
compensated by enhanced activation of the remaining Akt isoforms. These findings indicate that therapeutic
strategies targeting the activation of individual Akt isoforms will prove less effective than simultaneously inhibiting
the activity of all three Akt isoforms for the treatment of breast cancer.Background
The insulin-like growth factor (IGF) family has been im-
plicated in a number of human cancers including breast
cancer [1-5]. In particular, the type I IGF receptor or
IGF-IR has been found to be expressed at high levels in
39-93% of human breast cancers [6-9]. Originally, the
IGF-IR was associated with luminal breast cancer how-
ever more recent studies have found the IGF-IR in all
breast cancer subtypes [9-14]. Two different transgenic
mouse models have also shown the importance of IGF-
IR in mammary tumorigenesis. In a study by Carboni* Correspondence: rmoorehe@uoguelph.ca
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distribution, and reproduction in any mediumet al. [15] expression of a constitutively active IGF-IR in
mammary epithelial cells induced mammary tumor de-
velopment. The other transgenic model was developed
in our lab and this model overexpressed the wild type
IGF-IR in mammary epithelial cells in a doxycycline in-
ducible manner [16]. Overexpression of wild type IGF-
IR also resulted in the formation of mammary tumors.
One important signalling molecule downstream of the
IGF-IR is Akt. Akt is a serine-threonine kinase that lies
downstream of PI3K signaling [17-21]. There are 3 Akt
isoforms in mammals and each is transcribed from sep-
arate genes [22-25]. Based on genetic ablation of each
isoform in mice it appears that Akt1 regulates cell sur-
vival and/or proliferation based on the observation thated Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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smaller in size [26]. Akt2 appears to regulate glucose
homeostasis and Akt2−/− mice develop insulin-resistant
diabetes while Akt3 appears important in the brain as
Akt3−/− have impaired brain development [27,28]. The
function of Akt isoforms with respect to breast cancer
has been investigated in cell lines and transgenic models
of mammary tumorigenesis. In MDA-MB-231 human
breast cancer cells, which express low levels of activated
Akt, the overexpression of constitutively active forms of
Akt1 or Akt2 inhibited cell proliferation and migration
with little effect on apoptosis [29]. In a non-transformed
human mammary epithelial cell line (MCF-10A) gene-
tically altered to express high levels of IGF-IR, Akt1
downregulation reduced proliferation and enhanced mi-
gration while Akt2 downregulation reduced proliferation
but had not effect on migration [30].
The function of Akt isoforms has been studied in two
transgenic mammary tumor models, MMTV-neu and
MMTV-PyMT. MMTV-neu transgenic mice constitu-
tively overexpress erbB2 in mouse mammary epithelial
cells using the mouse mammary tumor virus (MMTV)
promoter. MMTV-PyMT transgenic mice express the
polyoma virus middle T antigen in mammary epithelial
cells using the MMTV promoter. In both models over-
expression of constitutively active Akt1 was shown to
delay mammary tumor formation but had no effect on
metastasis while the overexpression of activated Akt2 did
not affect tumor latency but did enhance tumor metasta-
sis [31]. In addition, ablation of Akt1 in MMTV-neu or
MMTV-PyMT transgenics inhibited tumor formation
while the ablation of Akt2 accelerated tumor formation
[32]. In addition, loss of Akt1 in MMTV-neu tumors en-
hanced their invasiveness.
In our MTB-IGFIR transgenic mice, we found that
Akt1 or Akt2 ablation significantly increased in tumor
latency and decreased tumor growth rate. Moreover, loss




Animals were housed and cared for following guidelines
established by the Central Animal Facility at the Univer-
sity of Guelph and the guidelines established by the
Canadian Council of Animal Care. This study was ap-
proved by the Animal Care Committee at the University
of Guelph.
Mice
MTB-IGFIR transgenic mice were generated in our lab
and have been previously described [16]. Akt1−/− and
Akt2−/− mice were purchased from Jackson Laboratories
(Bar Harbor, ME). Since the Akt1−/− and Akt2−/− micewere in a C57BL/6 background, these mice were
backcrossed 7 times with FVB mice to generate Akt1−/−
and Akt2−/− mice in the same genetic background as our
MTB-IGFIR transgenic mice. The MTB-IGFIR transgenic
mice were then mated with either Akt1−/− or Akt2−/− mice
until the appropriate genotypes were obtained. MTB-
IGFIR, MTB-IGFIR/Akt1−/− and MTB-IGFIR/Akt2−/−
mice were administered chow supplemented with 2 g of
doxycycline per gram of chow beginning when the mice
were 21 days of age.
Tumor measurement and collection
All mice were monitored 2 times per week by palpating
the mammary glands. Once a palpable mammary tumor
was identified the age of the mouse was recorded and
tumor growth was monitored using digital calipers. The
formula, volume = length × width2/2 was used for esti-
mating tumor volume. Tumor growth rate was calcu-
lated using the formula for specific growth rate (SGR);
[SGR = ln (V2/V1)/(t2-t1)] [33]. Once the mammary tu-
mors reached either 17 mm in diameter or 10% of the
mouse’s body weight, the mice were euthanized and the
mammary tumors were collected. Each mammary tumor
was collected and divided for fixation in formalin, cryo-
preservation in OCT and flash frozen.
Western blotting
Western blotting was performed as described in Jones
et al. [16]. All antibodies were obtained from Cell Sig-
nalling Technologies (Beverly, MA) except for the IGF-
IR antibody which was obtained from R&D Systems
(Minneapolis, MN) and the β-actin antibody which was
obtained from Sigma (Oakville, ON). All antibodies
were used at a 1:1000 dilution except for β-actin which
was used at a 1:5,000 dilution. Appropriate secondary
antibodies were obtained from Cell Signalling Tech-
nologies (Beverly, MA) and used at a dilution of 1:2,000.
Images were captured on a FluorChem 9900 gel docu-
mentation system (Alpha Innotech, San Leandro, CA)
and quantification of western blots was performed using
AlphaEase software (Alpha Innotech, San Leandro, CA).
Histology and immunohistochemistry
Mammary tumors and lungs were collected and
processed as previously described [16,34]. Immunohisto-
chemistry was performed as previously described [16].
Primary antibodies were used at a dilution of 1:200 and
were obtained from the following sources, anti-Ki67, anti-
cytokeratin 5 and anti-cytokeratin 14 (Abcam, Cambridge,
MA), anti-cytokeratin 18 (Research Diagnostics Inc,
Flanders, NJ), and anti-cytokeratin 8 (Fitzgerald In-
dustries International Inc, Concord, MA). Primary
antibodies were detected using a 1:200 dilution of
the appropriate secondary antibody and Sigma Fast
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Ki67 immunohistochemistry was quantified using Posi-
tive Pixel Count software v9 (Aperio, Vista, CA) follow-
ing slide scanning on a ScanScope CS slide scanner
(Aperio, Vista, CA).
Statistics
An ANOVA followed by a Duncan’s post-hoc test was
used to determine statistical significance since the
groups had an unequal sample size and the Duncan’s
test adjusts for sample size. Values with p<0.05 were
considered statistically significant.
Results
Previous characterization of the MTB-IGFIR transgenic
mice showed that mammary tumors expressing high
levels of IGF-IR also contained high levels of phosphory-
lated Akt [16]. However, it was not determined which of
the Akt isoforms were important in the MTB-IGFIR
mammary tumors. Therefore, as an initial experiment,
the levels of the three Akt isoforms were evaluated in
normal, wild type (WT) mammary tissue and in mam-
mary tumors of MTB-IGFIR transgenic mice. Evaluation
of Akt1, Akt2 and Akt3 revealed that Akt1 and Akt2 can
be detected in both WT mammary tissue and mammary
tumors (Figure 1) while Akt3 could not be detected in
either WT mammary tissue or mammary tumors.
Since Ak1 and Akt2 were consistently expressed in the
mammary tumors, MTB-IGFIR mice were crossed with
Akt1−/− and Akt2−/− mice to determine the roles of Akt1
and Akt2 in mammary tumorigenesis. To minimize any
effects that mouse strain may play on mammary tumori-
genesis, the Akt1−/− and Akt2−/− mice were backcrossed
7 times into a FVB/N background so that all mice were
in a FVB/N background (MTB-IGFIR transgenic mice
were created and maintained in a FVB/N background).
MTB-IGFIR/Akt1−/−, MTB-IGFIR/Akt2−/−, and MTB-
IGFIR mice were fed food supplemented with 2 g of
doxycycline per kilogram of rodent chow beginning
when the mice were 21 days of age. Mice overexpressing
IGF-IR and containing Akt1 and Akt2 developed tumorsFigure 1 The levels of Akt1 and Akt2. Western blot for Akt1 and
Akt2 in wild type (WT) mammary tissues from four different mice
and mammary tumors from four different MTB-IGFIR transgenic
mice. Akt3 was evaluated but could not be detected in any of the
samples. The WT tissue was taken from adult mice that had not
been exposed to doxycycline. β-actin served as a loading control.at approximately 56.5 days of age or 35.5 days after the
initiation of doxycycline supplemented food. This onset
is similar to what we previously published for these mice
[16]. In the MTB-IGFIR/Akt1−/− mice, tumor onset was
47.3 ± 3.1 days after supplying the mice with doxycycline
supplemented food (Table 1). This tumor onset was ap-
proximately 12 days longer than the MTB-IGFIR mice
and this difference was statistically significant. In the
MTB-IGFIR/Akt2−/− mice tumor onset was 43.6 ± 3.6
days after the addition of doxycycline to the food and
this delay in tumor onset was also statistically different
from the MTB-IGFIR mice (Table 1). Graphs showing
the tumor onset are presented in Figure 2. There were
no obvious differences in the number of tumors that de-
veloped in each animal or the number of animals with
lung metastasis (Table 1).
Tumor growth rates were also evaluated using the for-
mula for Specific Growth Rate (SGR) [33]. It was ob-
served that mammary tumors in MTB-IGFIR/Akt1−/−
mice had SGRs that were approximately half that of the
MTB-IGFIR mice. This difference in growth rate was sig-
nificant. The mammary tumors in MTB-IGFIR/Akt2−/−
mice had growth rates that were approximately 36%
slower than MTB-IGFIR mice and this difference was also
statistically significant. Figure 3 shows a scatter plot with
best fit exponential tumor growth curves to illustrate the
differences in mammary tumor growth rates. As indicated
in these plots there was some variability regarding growth
rates of mammary tumors in MTB-IGFIR/Akt1−/− and
MTB-IGFIR/Akt2−/− mice, however, the majority of the
tumors grew at a slower rate than the mammary tumors
of MTB-IGFIR mice.
To determine whether tumor proliferation was affected
in either the MTB-IGFIR/Akt1−/− or MTB-IGFIR/Akt2−/−
mice Ki67 immunohistochemistry was performed. It was
observed that tumor cell proliferation in the MTB-
IGFIR/Akt1−/− tumors was reduced approximately 55%
compared to MTB-IGFIR tumors while proliferation
rates in the MTB-IGFIR/Akt2−/− tumors were reduced
approximately 20% (Figure 4). The data was however
quite variable and thus neither result were statistically
significant.
To confirm protein levels in the mammary tumors,
western blotting was performed for IGF-IR, Akt1, Akt2,
phosphorylated Akt (pAkt), Erk1/2, phosphorylated
Erk1/2 (pErk1/2), Stat3 and phosphorylated Stat3
(pStat3). As shown in Figure 5, mammary tumors with
normal levels of Akt1 and Akt2 had similar levels of the
IGF-IR as mammary tumors null for Akt1 or null for
Akt2 (Figure 5A,B). The levels of Akt1 were undetect-
able in MTB-IGFIR/Akt1−/− mammary tumors while the
levels of Akt2 were similar in MTB-IGFIR mammary tu-
mors, and mammary tumors from MTB-IGFIR/Akt1−/−
mice. Similarly, the levels of Akt2 were undetectable in
Table 1 Tumor characterization
Genotype # of mice Tumor onset (days) Specific growth rate # of tumors at time of death # of mice with lung metastases
MTB-IGFIR 11 35.5 ± 2.0 0.14 ± 0.02 3.2 ± 0.2 2/11
MTB-IGFIR/Akt1−/− 6 47.3 ± 3.1* 0.07 ± 0.01* 2.8 ± 0.8 1/6
MTB-IGFIR/Akt2−/− 6 43.6 ± 3.6* 0.09 ± 0.02* 3.5 ± 0.6 1/6
*significantly different from WT as determined by a Duncan’s test using WT, Akt1−/− and Akt2−/− mice.
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in MTB-IGFIR mammary tumors and mammary tumors
from MTB-IGFIR/Akt2−/− mice. The levels of Akt3
could be detected at very low but similar levels in the
mammary tumors from three different genotypes (data
not shown). Despite the loss of Akt1 or Akt2, the mam-
mary tumors from MTB-IGFIR/Akt1−/− and MTB-
IGFIR/Akt2−/− mice had levels of phosphorylated Akt
similar to the mammary tumors that developed in MTB-
IGFIR mice. The levels of some of the signalling mole-
cules downstream of phosphorylated Akt were also
found at similar levels in all genotypes except for higher
levels of phosphorylated Erk1/2 associated with MTB-
IGFIR/Akt2−/− tumors (Figure 5A,B).
Since Akt1 and Akt2 have been implicated in epithelial
to mesenchymal transition in some mammary models
[30,35,36], immunohistochemical analysis of cytokeratins
5, 8, 14 and 18 was performed to determine whether the
type of mammary tumors that developed in MTB-IGFIR/
Akt1−/− or MTB-IGFIR/Akt2−/− mice differed from the
tumors that developed in MTB-IGFIR mice. The major-
ity of the mammary tumors in each genotype contained
cells that expressed moderate or high levels of cyto-
keratin 8 (Figure 6A-C) and/or 18 (data not shown)Figure 2 Mammary tumor onset in MTB-IGFIR, MTB-IGFIR/Akt1-/- and
in MTB-IGFIR/Akt1-/- mice (red line; n=6), MTB-IGFIR/Akt2-/- mice (green line
MTB-IGFIR mice were used for both comparisons.indicating these cells were luminal in nature. However,
some tumors contained clusters of cytokeratin 5 and 14
positive cells and these clusters were independent of
Akt genotype (Figure 6D-I). This mixture of tumor
with luminal and basal characteristics was observed in
the original characterization of the MTB-IGFIR mam-
mary tumors [16].
Discussion
Since Akt is one of the most hyperactive kinases in can-
cer [17] it is an attractive therapeutic target. However,
there are three Akt isoforms and our understanding
about the functions of the individual Akt isoforms in
normal and cancerous tissue is incomplete. In our study
we found that loss of either Akt1 or Akt2 produced a
small but significant delay in tumor onset and a small
but significant decrease in tumor growth rate.
Delayed mammary tumor onset and reduced tumor
growth rate observed in the MTB-IGFIR/Akt1−/− mice
was consistent with the findings of Maroulakou et al.
[32] which showed that loss of Akt1 significantly delayed
tumor onset and reduced tumor growth in MMTV-neu
and MMTV-PyMT transgenic mice. However, loss of
Akt1 in the MMTV-neu and MMTV-PyMT transgenicMTB-IGFIR/Akt2-/- mice. The graph shows mammary tumor onset
; n=6) and MTB-IGFIR mice (black line; n=11). The same group of
Figure 3 Mammary tumor volume in MTB-IGFIR, MTB-IGFIR/Akt1-/- and MTB-IGFIR/Akt2-/- mice. Graphs showing tumor volumes in
(A) MTB-IGFIR/Akt1−/− mice (red squares, red lines; n=6) compared to MTB-IGFIR mice (black circles, black lines; n=11) and (B) MTB-IGFIR/Akt2−/−
mice (green diamonds, green lines; n=6) compared to MTB-IGFIR mice (black circles, black lines; n=11). Tumor volumes for each mouse were
plotted as a scatter plot and the best fit, exponential line was drawn. The same group of MTB-IGFIR mice were used for both comparisons.
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than that observed in the MTB-IGFIR transgenic mice.
Maroulakou et al. [32] also observed that loss of Akt2
enhanced mammary tumorigenesis, a result not ob-
served in the MTB-IGFIR/Akt2−/− mice. In addition,Figure 4 Mammary tumor proliferation in MTB-IGFIR, MTB-
IGFIR/Akt1-/- and MTB-IGFIR/Akt2-/- mice. The mitotic index of
mammary tumors from MTB-IGFIR mice (black bar; n=11), MTB-
IGFIR/Akt1−/− mice (grey bar; n=6) and MTB-IGFIR/Akt2−/− mice
(white bar; n=6) was determined using Ki67 immunohistochemistry.
The bars represent the mean and standard error of the percentage
of tumor cells positive for Ki67 staining.Maroulakou et al. [32] observed that loss of Akt1
reduced lung metastasis in MMTV-PyMT but not
MMTV-neu transgenic mice. Neither loss of Akt1 nor
Akt2 significantly affected metastasis in the MTB-IGFIR
transgenic mice however it should be noted that de-
creased metastatic rate in the MTB-IGFIR transgenic
mice may be difficult to detect as these tumors inher-
ently have a relatively low metastatic rate.
There are several differences in the studies involving
the MMTV-neu or MMTV-PyMT transgenics and our
MTB-IGFIR transgenics. First, the transgene used to
produce the mammary tumors was different. In our case,
the IGF-IR drove mammary tumorigenesis while in the
study by Maroulakou et al. [32], either ErbB2 or the
polyoma virus middle T antigen were used. Although
IGF-IR and ErbB2 are both tyrosine kinase receptors
that initiate similar signalling cascades, tumors induced
by these two transgenes are distinct. Using gene expres-
sion profiles, we previously showed that our MTB-IGFIR
mammary tumors did not cluster with the MMTV-neu
or MMTV-PyMT mammary tumors [37]. The MTB-
IGFIR mammary tumors clustered most closely with hu-
man basal tumors [37] while the MMTV-neu mammary
tumors have been reported to cluster more closely with
human luminal breast cancers [38]. The MMTV-PyMT
transgenics, like the MMTV-neu transgenics, clustered
most closely with human luminal breast cancers [38].
Another potential significant difference was the strain
of the mice. The study by Maroulakou et al. [32] did not
specify the mouse strains used however Akt1−/− and
Akt2−/− mice are typically in a C57BL/6 background
while MMTV-neu and MMTV-PyMT transgenic mice
are typically in a FVB background. Therefore, it is
Figure 5 The levels of signaling proteins in mammary tumors from MTB-IGFIR, MTB-IGFIR/Akt1-/- and MTB-IGFIR/Akt2-/- mice. Western
blot for IGF-IR, Akt1, Akt2, phosphorylated Akt (pAkt; Ser473), phosphorylated Erk (pErk), Erk, phosphorylated Stat3 and Stat3 in (A) mammary
tumors from MTB-IGFIR transgenic mice compared to MTB-IGFIR/Akt1−/− mice or (B) mammary tumors from MTB-IGFIR transgenic mice
compared to MTB-IGFIR/Akt2−/− mice. Each lane represents tissue from a different animal and the relative abundance of each protein is presented
in the bar graph below the western. *p<0.05 as determined by a Student’s T-test.
Figure 6 Cytokeratin expression in mammary tumors from MTB-IGFIR, MTB-IGFIR/Akt1-/- and MTB-IGFIR/Akt2-/- mice.
Immunohistochemistry for cytokeratin 8 (A-C), cytokeratin 5 (D-F) or cytokeratin 14 (G-I) in mammary tumors from MTB-IGFIR mice (A,D,G), MTB-
IGFIR/Akt1−/− mice (B,E,H) or MTB-IGFIR/Akt2−/− mice (C,F,I). The brown color indicates the presence of each protein while the nuclei of the cells
are blue due to hematoxylin staining. Scale bars, 100 μm.
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strain background. In our study, Akt1−/− and Akt2−/−
mice were backcrossed 7 times into a FVB background
and mated with MTB-IGFIR transgenic mice which are
on a FVB background. Therefore, our studies were
performed on an essentially pure genetic background. It
should be noted that we also attempted to backcross our
MTB-IGFIR transgenic mice into a C57BL/6 background
however even on the first backcross, these mice failed to
form mammary tumors (unpublished observations).
In our study, alternative signaling pathways appeared to
compensate for the loss of Akt1 or Akt2. This was evident
by the fact that Akt phosphorylation did not decrease in
mice lacking either Akt1 or Akt2. Since the total level of
Akt phosphorylation did not diminish despite the absence
of Akt1 or Akt2, it appears that the tumor cells compen-
sated by increasing the phosphorylation of the remaining
Akt isoforms. An increase in Erk phosphorylation was also
observed in the MTB-IGFIR/Akt2−/− tumors compared to
MTB-IGFIR tumors. Erk1/2 signaling promotes survival
and may have contributed to tumor cell survival in the
absence of Akt2. Compensation between these pathways
has been observed in mammary tumors in previously pub-
lished studies [39,40]. It is also possible that signaling
pathways not evaluated in this study may have compen-
sated for the absence of Akt1 or Akt2. The paper by
Maroulakou et al. [32] did not evaluate the activation of
intracellular signaling molecules in their tumors so com-
parisons to our study cannot be made.
Despite previous reports implicating Akt in EMT
[30,35,36] we found no evidence that loss of Akt1 or
Akt2 affected tumor cell morphology in the MTB-IGFIR
transgenic mice. However, since EMT was not a focus of
this study this property was not extensively examined in
the current study. EMT is a process whereby epithelial
cells convert to a mesenchymal morphology and ex-
press genes typically associated with mesenchymal cells
(reviewed in [41-44]). EMT is thought to increase the
invasiveness of breast cancers [45-49].
Conclusion
Although loss of Akt1 or Akt2 significantly inhibited mam-
mary tumor onset and growth rates these effects were very
modest. It is probable that the loss of Akt1 or Akt2 was
compensated for by the remaining Akt isoforms and/or
alternative signaling pathways in the tumor cells. Compen-
sation has important clinical implications in that tumors
are unlikely to significantly respond to therapeutic agents
targeting individual signaling pathways or individual pro-
tein isoforms within signaling pathways. Future studies
using Akt inhibitors for the treatment of breast cancer
should employ Akt inhibitors that target both Akt1 and
Akt2 in combination with inhibitors that target additional
signaling pathways such as the MAPK signaling pathway.Abbreviations
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